Elute received FDA 510(k) clearance to market BonVie+, a novel bone void filler implant.
BonVie+ is designed for controlled resorption and replacement by new bone.
“This new era in resorbable bone graft fillers represents over a decade of innovation, equipping clinicians with unparalleled consistency in bone restoration and predictable clinical results,” said Ashok Khandkar, CEO of Elute.
Elute received FDA 510(k) clearance to market BonVie+, a novel bone void filler implant.
BonVie+ is designed for controlled resorption and replacement by new bone.
"This new era in resorbable bone graft fillers represents over a decade of innovation, equipping clinicians with unparalleled...
Elute received FDA 510(k) clearance to market BonVie+, a novel bone void filler implant.
BonVie+ is designed for controlled resorption and replacement by new bone.
“This new era in resorbable bone graft fillers represents over a decade of innovation, equipping clinicians with unparalleled consistency in bone restoration and predictable clinical results,” said Ashok Khandkar, CEO of Elute.
Copy to clipboard 
